Guidance
This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.
In October 2023, we updated the recommendation on suspected cancer pathway referral for possible bladder cancer in line with NHS England’s standard on faster diagnosis of cancer. People should have a diagnosis or ruling out of cancer within 28 days of referral.
Recommendations
This guideline includes recommendations on:
- assessment
- information and support
- treatment to improve bladder storage and emptying, and for stress incontinence
- management with catheter valves and ileal conduit diversion
- monitoring and surveillance protocols
- potential complications
Who is it for?
- Healthcare professionals
- Commissioners and providers
- People with urinary incontinence and neurological disease and their families and carers
Is this guideline up to date?
We checked this guideline in January 2019. We found no new evidence that affects the recommendations in this guideline.
Guideline development process
How we develop NICE guidelines
This guideline was previously called neurological disease: management of lower urinary tract dysfunction in neurological disease.
Your responsibility
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.